期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多西紫杉醇联合替吉奥治疗晚期乳腺癌的临床疗效 被引量：3

原文传递
导出
摘要 目的观察多西紫杉醇联合替吉奥治疗晚期乳腺癌的临床疗效。方法对26例晚期乳腺癌患者采用多西紫杉醇75mg/m2联合替吉奥40-60mg/m2治疗,3周为1个周期。治疗2个周期后评价疗效,计算有效率(RR)、疾病控制率(DCR),观察肿瘤进展时间(TTP)、不良反应发生情况。结果 26例患者RR为50.0%,DCR为80.8%。随访至2014年10月,TTP为1.5-11.0个月,中位TTP为7.0个月。主要不良反应为白细胞减少、胃肠道反应等,多为1、2级,均可耐受。结论多西紫杉醇联合替吉奥治疗晚期乳腺癌疗效肯定,不良反应较小,耐受性好,值得临床推广。
作者 赵霞 马靓 陈平
机构地区 盐城市第一人民医院肿瘤内科
出处 《江苏医药》 CAS 2015年第15期1806-1808,共3页 Jiangsu Medical Journal
关键词 多西紫杉醇 替吉奥 乳腺癌
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Mandelblat J,Bashir T,Budman DR.Capecitabine-docetaxel combination treatment[J].Expert Rev Anticancer Ther,2006,6(9):1169-1178.
  • 2Biganzoli L,Minisini A,Aapro M,et al.Chemotherapy for metastatic breast cancer[J].Curr Opin Obstet Gynecol,2004,16(1):37-41.
  • 3Jones SE,Erban J,Overmoyer B,et al.Randomized phaseⅢstudy of docetaxel compared with paclitaxel in metastatic breast cancer[J].J Clin Oncol,2005,23(24):5542-5551.
  • 4Shirasaka T,Shimamato Y,Ohshimo H,et al.Development of a novel form of an oral 5-fluorouracil derivative(S-1)directed to the potentiation of the tumor selective cytotoxicity of5-fluorouracil by two biochemical modulators[J].Anticancer Drugs,1996,7(5):548-557.
  • 5Saek T,Takashima S,Sano M,et al.A PhaseⅡStudy of S-1in patients with matastatic breast cancer—a Japanese trial by the S-1 Cooperative Study Group,Breast Cancer Working Group[J].Breast Cancer,2004,11(2):194-202.
  • 6马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502. 被引量：54
  • 7Vallbhmer D,Yang DY,Kuramochi H,et al.DPD is a molecular determinant of capecitabine efficacy in colorectal cancer[J].Int J Oncol,2007,31(2):413-418.
  • 8Suto A,Kubota T,Fukushima M,et al.Antitumor effect of combination of S-1and docetaxel on the human breast cancer xenograft transplanted into SCID mice[J].Oncol Rep,2006,15(6):1517-1522.
  • 9Kondo N,Murakami Y,Uemura K,et al.Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection[J].J Surg Oncol,2011,104(2):146-154.
  • 10谢家印,向大开,王东,杜佳,邹华,罗维.多西他赛联合替吉奥治疗复发转移性乳腺癌的临床分析[J].第三军医大学学报,2011,33(22):2414-2416. 被引量：13

二级参考文献38

  • 1袁泉.羟基脲、替加氟及亚叶酸钙治疗27例晚期鼻咽癌临床观察[J].中国医药导报,2007,4(07Z):54-55. 被引量：14
  • 2Mansour E G, Gray R, Shatila A H, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis -- an intergroup study[J]. J Clin Oncol, 1998, 16(11) : 3486-3492.
  • 3Goldhirsch A, Glick J H, Gelber R D, et aL Meeting highlights: In- ternational consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer [J]. J Clin Oneol, 2001, 19(18): 3817 -3827.
  • 4Hara F, Kiyoto S, Takahashi M, et al. Efficacy and safety of S-1 in patients with metastatic breast cancer: retrospective review in a single institution[J]. Oncology, 2010, 79 (3/4): 273-277.
  • 5Shien T, Shimizu C, Akashi-Tanaka S, et al. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients [ J ]. [ My paper ] Jpn J Clin Oncol, 2008, 38 (3) : 172 - 175.
  • 6Baur M, van-Oosterom A T, Dieras V, et al. A phase Ⅱ trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer[J]. J Cancer Res Clin Oncol, 2008, 134(2) : 125 -135.
  • 7Saek T, Takashima S, Sane M, et al. A phase Ⅱ study of S-1 in pa- tients with metastatic breast cancer -- a Japanese trial by the S-1 Coop- erative Study Group, Breast Cancer Working Group [ J ]. Breast Canc- er, 2004, 11(2) : 194 -202.
  • 8Sato Y, Takayama T, Sagawa T, et al. Phase Ⅱ study of S-1, do- cetaxel and cisplatin combination chemotherapy in patients with unre- sectable metastatic gastric cancer [ J ]. Cancer Chemother Pharmacol, 2010, 66(4): 721 -728.
  • 9Suto A, Kubota T, Fukushima M, et al. Antitumor effect of combina- tion of S-1 and docetaxel on the human breast cancer xenograft trans- planted into SCID mice[J]. Oncol Rep, 2006, 15(6) : 1517 -1522.
  • 10Taira N, Aogi K, Ohsumi S, et al. S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer [J].Breast Cancer, 2006, 13(2): 220-224.

共引文献90

同被引文献27

  • 1Lavaud P,Rousseau B,Ajgal Z,et al.Bi-weekly very-high-dose lapatinib:an easy-to-use active option in HER-2-positive breast cancerpatients with meningeal carcinomatosis[J].Breast Cancer Res Treat,2016,157(1):191-192.
  • 2Coutant C,Jankowski C,Portha H,et al.Assessment of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy inbreast cancer:before or after?[J].Gynecol Obstet Fertil,2016,44(6):345-349.
  • 3Klintman M,Buus R,Cheang MC,et al.Changes in expression of genes representing key biologic processes after neoadjuvant chemotherapy in breast cancer,and prognostic implications in residual disease[J].Clin Cancer Res,2016,22(10):2405-2416.
  • 4Asif HM,Sultana S,Ahmed S,et al.HER-2positive breast cancer-a mini-review[J].Asian Pac J Cancer Prev,2016,17(4):1609-1615.
  • 5Wang YJ,Huang XY,Mo M,et al.Serum tumor marker levels might have little significance in evaluating neoadjuvant treatment response in locally advanced breast cancer[J].Asian Pac J Cancer Prev,2015,16(11):4603-4608.
  • 6Fejzi'c H,Mujagi'c S,Azabagi'c S,et al.Tumor marker CA 15-3in breast cancer patients[J].Acta Med Acad,2015,44(1):39-46.
  • 7Ramsey SD,Henry NL,Gralow JR,et al.Tumor marker usage and medical care costs among older early-stage breast cancer survivor[J].J Clin Oncol,2015,33(2):149-155.
  • 8Serrill JD,Wan X,Hau AM,et al.Coibamide A,a natural lariat depsipeptide,inhibits VEGFA/VEGFR2expression and suppresses tumor growth in glioblastoma xenografts[J].Invest New Drugs,2016,34(1):24-40.
  • 9Chen Z,Guan H,Yuan H,et al.Serum thymidine kinase 1is a reliable maker for the assessment of the risk of developing malignancy:A case report[J].Oncol Lett,2015,10(3):1669-1673.
  • 10De Santi M,Annibalini G,Barbieri E,et al.Human IGF1proforms induce breast cancer cell proliferation via the IGF1receptor[J].Cell Oncol(Dordr),2016,39(2):149-159.

引证文献3

二级引证文献17

江苏医药
2015年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部